PhRMA CEO Steve Ubl to Step Down After Decade of Leading Drug Lobby Through Pricing Wars and Pandemic

Steve Ubl, the chief executive of the Pharmaceutical Research and Manufacturers of America (PhRMA), is stepping down at the end of the year. His departure marks the end of a more than decade-long tenure leading the primary trade group for brand-name drug manufacturers, a period defined by intense political battles over prescription drug costs and the unprecedented challenges of the Covid-19 pandemic.

Ubl helmed PhRMA during a time of sustained scrutiny and aggressive political attacks on drug pricing. The organization faced significant pressure as Democrats successfully passed legislation empowering Medicare to negotiate directly on the price of certain medications—a landmark policy shift long opposed by the industry. His leadership navigated the complex intersection of public health crises, legislative threats, and the industry's defense of its pricing models.

The exit of a long-serving CEO at the pinnacle of pharmaceutical lobbying signals a potential inflection point for the industry's Washington strategy. It comes as drug pricing remains a central political issue, with ongoing pressure from lawmakers and the public. The search for a successor will be closely watched, as the new leader will inherit the task of defending the sector's interests in an increasingly hostile regulatory and political environment shaped by Ubl's era.